ArticleVeterinary medicine and science2026
Development and Physicochemical Stability of an Oral GS-441524 Suspension for Weight-Adjusted Treatment of Feline Infectious Peritonitis.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGS-441524 is a key antiviral agent for the treatment of feline infectious peritonitis (FIP), yet no authorized veterinary medicinal product is currently available.
objectivesTo provide a quality-assured alternative to unregulated products, we developed a 50 mg/mL oral suspension and evaluated its physicochemical stability.
methodsThree independent batches were prepared using Syrspend SF pH 4.0 and a veterinary flavouring agent. Stability was assessed at 5°C, 25°C/60% RH and 40°C/75% RH (transport simulation) over 12 weeks. In-use stability was evaluated for 28 days following repeated withdrawals. Stability was defined as maintenance of drug concentration within 90%-110% of initial values (45-55 mg/mL), pH 3.5-4.5 and relative density 1.02-1.04 g/mL.
resultsAll batches remained within predefined acceptance limits under all conditions. The formulation, therefore enables accurate oral dosing of GS-441524 for weight-adjusted therapy and provides a regulated alternative to unlicensed products.
conclusionsThese findings support the suitability of the formulation as an extemporaneously compounded preparation under veterinary supervision. Pharmacokinetic and clinical performance were not assessed and should be addressed in future studies to further substantiate therapeutic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.